Catalyst Dossier · compiled by CeliA 🧫

Organon & Co. (OGN)

Pharmaceutical Preparations · market cap $3.5B · as of 2026-07-14

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Organon & Co. (OGN) is a specialty pharmaceutical company spun out of Merck, focused on women's health (reproductive medicine, contraception, HRT), biosimilars, and established brands across psychiatry and anesthesia. With ~$6.2B in annual revenue but $7.47B in net debt against a $3.55B market cap, the equity is a highly leveraged claim on a largely mature, off-patent portfolio. The August 4, 2026 earnings print is the nearest near-term catalyst.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
MK0217, alendronate sodium / Duration of Treatment : 2 Years	Phase 3	Osteoporosis, Postmenopausal
Corifollitropin alfa	Phase 3	In Vitro Fertilization
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg	Phase 2	Asthma
Tibolone 2.5 mg	Phase 3	Postmenopausal Women
Desloratadine 2.5 mg	Phase 2	Post-nasal Drip
MK0663, Etoricoxib / Duration of Treatment : 12 Weeks	Phase 3	Recurrent Low Back Pain
A-Phase: tirofiban; Z-Phase simvastatin	Phase 3	Acute Coronary Syndrome
Radiopaque Implanon	Phase 3	Contraception
NOMAC-E2	Phase 3	Contraception
Desloratadine (Clarinex)	Phase 3	Allergic Rhinitis
tibolone	Phase 3	Sexual Dysfunction
Desloratadine 5 mg	Phase 3	Eczema
tapinarof cream, 1%	Phase 3	Plaque Psoriasis
etoricoxib	Phase 2	Rheumatoid Arthritis
phenylephrine	Phase 3	Rhinitis, Allergic, Seasonal
5-mg Desloratadine	Phase 3	Rhinitis, Allergic, Seasonal
asenapine	Phase 3	Schizophrenia
Mometasone Furoate Nasal Spray (MFNS)	Phase 3	Nasal Polyps
Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI	Phase 3	Asthma
DRSP-EE	Phase 3	Contraception

Price & technical context

3-month

+2.3%

6-month

+57.6%

12-month

+35.0%

52-wk range

$5.70–$13.56

vs 50-day MA

+0.6%

vs 200-day MA

+41.9%

Realized vol

66.1%

Max drawdown

-75.2%

Daily closes through 2026-07-31. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.